New drug cocktail aims to stall advanced lung cancer
NCT ID NCT06497530
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of two drugs, lurbinectedin and serplulimab, can help keep extensive-stage small cell lung cancer from growing when used as maintenance therapy after initial chemo-immunotherapy. About 30 adults whose cancer has not worsened after four cycles of standard treatment will receive the combo every three weeks. The main goal is to see how long the cancer stays controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lurbinectedin and serplulimab (drug combination)
- What this could lead to
- If successful, this could offer a new maintenance option to help keep extensive-stage small cell lung cancer under control for longer after initial treatment.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The first affiliated hospital of Guangzhou medical university
RECRUITINGGuangzhou, Guangdong, 51000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink tough lung cancers?
- Can a smartphone app ease the burden of advanced lung cancer?
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New combo shows promise for tough lung cancer
- New hope for tough lung cancer: combo therapy enters phase II trial